Unichem Laboratories Analyst Review May 2026

This Unichem Laboratories analyst review for May 2026 covers the key data investors need for UNICHEMLAB at its current price of Rs 565. Unichem Laboratories (NSE: UNICHEMLAB) is a pharmaceutical company with a market capitalisation of approximately Rs 4,200 crore, with branded formulations in cardiovascular, antibiotics, and dermatology. The analyst consensus target of Rs 680 implies meaningful upside, and this Unichem Laboratories analyst review examines technical levels, business segments, valuation, and key risks for UNICHEMLAB through FY27.

Click Here – Get Free Investment Predictions

Unichem Laboratories Company Snapshot May 2026

Unichem’s India branded business (65 percent of revenue) focuses on chronic cardiovascular and CNS therapies. The US generics business (Unichem Pharmaceuticals USA) contributes through oral solids and specialty products. The table below summarises the key data referenced in this Unichem Laboratories analyst review.

Parameter	Value
NSE Ticker	UNICHEMLAB
Sector	Pharmaceuticals – Branded and Generic
CMP (May 2026)	Rs 565
52 Week High	Rs 868
52 Week Low	Rs 528
Market Cap	Rs 4,200 Crore
Trailing P/E	22x
Analyst Consensus Target	Rs 680
Bull Case Target	Rs 900
Bear Case Target	Rs 520

Analyst Insight in This Unichem Laboratories Analyst Review

Senior Research Analyst Ankit Jaiswal flags Unichem Laboratories as a stock to watch in May 2026. At Rs 565, Ankit Jaiswal identifies key support in the Rs 539 to Rs 537 band and resistance near Rs 599. He suggests watching Unichem Laboratories for a potential move toward Rs 680, subject to Pharmaceuticals – Branded and Generic sector momentum and Nifty 50 direction. Ankit Jaiswal’s view is one input in this Unichem Laboratories analyst review and does not constitute a trade recommendation.

Technical Analysis in This Unichem Laboratories Analyst Review

At Rs 565, UNICHEMLAB is trading within its 52-week band of Rs 528 to Rs 868. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 539 to Rs 537 band while resistance is seen in the Rs 599 to Rs 622 zone. A sustained move above Rs 599 could open the path toward the analyst consensus target of Rs 680 as outlined in this Unichem Laboratories analyst review.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

• Support Zone: Rs 539 to Rs 537 – investors tracking this Unichem Laboratories analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for UNICHEMLAB.
• Resistance Zone: Rs 599 to Rs 622 – a sustained close above Rs 599 would be a positive breakout signal worth flagging in this Unichem Laboratories analyst review.
• Medium-Term Target: The analyst consensus of Rs 680 represents the base-case upside scenario in this Unichem Laboratories analyst review.

Business Segment Analysis

India Branded Pharmaceuticals (Cardiovascular, CNS)

This is the primary revenue and margin driver for Unichem Laboratories, directly supporting the earnings trajectory toward the consensus target of Rs 680.

US Generics (Oral Solids and Specialty Products)

This segment adds scale and diversification to Unichem Laboratories’s business model and is a meaningful EPS contributor through FY27 and FY28.

International Markets and Emerging Market Exports

This represents the medium-term growth frontier for Unichem Laboratories and a key re-rating catalyst over the next 12 to 24 months.

Valuation in This Unichem Laboratories Analyst Review

At Rs 565, Unichem Laboratories trades at a trailing P/E of 22x. This Unichem Laboratories analyst review presents three scenarios: a bull case of Rs 900 on strong earnings delivery and sector tailwinds, a base case of Rs 680 at analyst consensus, and a bear case of Rs 520 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Unichem Laboratories analyst review.

Scenario	Target Price	Key Condition
Bull Case	Rs 900	Strong earnings delivery and sector re-rating
Base Case (Consensus)	Rs 680	Moderate growth, analyst consensus estimate
Bear Case	Rs 520	Earnings miss or macro headwinds

Trade Outlook for Unichem Laboratories

Based on the technical and fundamental analysis in this Unichem Laboratories analyst review, investors might watch UNICHEMLAB near the support zone of Rs 539 to Rs 537 for potential opportunities. A flag above Rs 599 could suggest improving momentum toward Rs 680. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Unichem Laboratories in FY27

A well-rounded Unichem Laboratories analyst review must assess downside risks. Key risks for Unichem Laboratories include a macro slowdown affecting Pharmaceuticals – Branded and Generic sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in UNICHEMLAB.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Unichem Laboratories Analyst Review Verdict for 2026

This Unichem Laboratories analyst review concludes that at Rs 565, UNICHEMLAB offers a defined risk-reward with a consensus target of Rs 680. The 52-week range of Rs 528 to Rs 868 provides context on the current entry point. Use this Unichem Laboratories analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on UNICHEMLAB.

Frequently Asked Questions: Unichem Laboratories Analyst Review 2026

What is the analyst target for Unichem Laboratories in 2026?

The analyst consensus target is Rs 680, with a bull case of Rs 900 and a bear case of Rs 520. This Unichem Laboratories analyst review recommends monitoring Q1 FY27 earnings for confirmation.

Is Unichem Laboratories a good investment at Rs 565?

At Rs 565 with a P/E of 22x and a consensus target of Rs 680, this Unichem Laboratories analyst review is constructive for medium to long-term investors in the Pharmaceuticals – Branded and Generic sector. Always consult a SEBI-registered advisor before investing.

What is Unichem Laboratories’s 52-week high and low?

The 52-week high is Rs 868 and the 52-week low is Rs 528. At Rs 565, UNICHEMLAB is positioned within this range as detailed in this Unichem Laboratories analyst review.

What are the key risks for Unichem Laboratories?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals – Branded and Generic sector, all assessed in this Unichem Laboratories analyst review.

Where can I track live data for Unichem Laboratories?

Track Unichem Laboratories’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Unichem Laboratories analyst review.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.